MXPA03006855A - Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion. - Google Patents
Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.Info
- Publication number
- MXPA03006855A MXPA03006855A MXPA03006855A MXPA03006855A MXPA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A
- Authority
- MX
- Mexico
- Prior art keywords
- heart failure
- cholesterol levels
- diiodothyropropionic acid
- chronic heart
- treat chronic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion de los Solicitantes incluye un metodo para tratar a un paciente que tenga insuficiencia cardiaca congestiva, mediante la administracion de una cantidad terapeuticamente efectiva de acido 3,5-diyodotiropropionico. La invencion de los Solicitantes incluye ademas un metodo para reducir los niveles de colesterol en sangre de un paciente, mediante la administracion de una cantidad terapeuticamente efectiva de acido 3,5-diyodotiropropionico. La invencion de los Solicitantes incluye ademas un metodo sintetico para preparar acido 3,5-diyodotiropropionico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/774,994 US6534676B2 (en) | 2001-01-31 | 2001-01-31 | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
| PCT/US2002/003162 WO2002060389A2 (en) | 2001-01-31 | 2002-01-31 | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03006855A true MXPA03006855A (es) | 2004-03-12 |
Family
ID=25102976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03006855A MXPA03006855A (es) | 2001-01-31 | 2002-01-31 | Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6534676B2 (es) |
| EP (1) | EP1432310A4 (es) |
| JP (1) | JP2004522747A (es) |
| AU (1) | AU2002243801B2 (es) |
| CA (1) | CA2436421C (es) |
| MX (1) | MXPA03006855A (es) |
| WO (1) | WO2002060389A2 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504435B2 (en) * | 2001-01-31 | 2009-03-17 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for stimulating weight loss and/or for lowering triglycerides in patients |
| US6716877B2 (en) * | 2001-01-31 | 2004-04-06 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels |
| US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
| WO2005027895A2 (en) * | 2003-09-15 | 2005-03-31 | Ordway Research Institute | Thyroid hormone analogs and methods of use in angiogenesis |
| US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| CA2546601A1 (en) * | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| JP2008513461A (ja) * | 2004-09-15 | 2008-05-01 | オードウェイ リサーチ インスティテュート | 血管形成を促進する甲状腺ホルモンアナログ |
| CA2606498C (en) * | 2005-05-26 | 2016-08-09 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
| US20090022806A1 (en) * | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
| US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
| US9220788B2 (en) | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| WO2007035612A2 (en) | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
| JP2010513526A (ja) * | 2006-12-22 | 2010-04-30 | シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド | 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用 |
| AU2008219585A1 (en) * | 2007-02-27 | 2008-09-04 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. |
| EP2199271A4 (en) * | 2007-08-31 | 2011-05-18 | Mitsubishi Gas Chemical Co | METHOD FOR PRODUCING PHENOL DERIVATIVES SUBSTITUTED WITH IODINE AT THE ORTHO POSITION |
| WO2010075332A1 (en) * | 2008-12-23 | 2010-07-01 | Charitable Leadership Foundation | Small molecule ligands of the integrin rgd recognition site and methods of use |
| US9180107B2 (en) * | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
| US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
| RU2728790C2 (ru) * | 2014-02-10 | 2020-07-31 | Фред Хатчинсон Кансэр Рисёч Сентер | Лечение сердечного приступа и ишемического повреждения соединениями галогена |
| WO2017214299A1 (en) | 2016-06-07 | 2017-12-14 | Nanopharmaceuticals, Llc | NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS |
| BR112019010249A2 (pt) | 2016-11-21 | 2019-09-10 | Viking Therapeutics Inc | método de tratamento de doença de armazenamento de glicogênio |
| US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| US11787828B2 (en) | 2018-03-22 | 2023-10-17 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
| US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
| CA3261860A1 (en) * | 2022-07-11 | 2024-01-18 | The University Of Miami | METHODS AND FORMULATIONS FOR THE PRENATAL TREATMENT OF ALLAN-HERNDON-DUDLEY SYNDROME |
| US12390432B2 (en) | 2022-07-11 | 2025-08-19 | PriZm, LLC | Methods for treating allan-herndon-dudley syndrome |
| CA3261850A1 (en) * | 2022-07-11 | 2024-01-18 | Dexcel Pharma Technologies Ltd. | 3,5-DIIODOTHYROPROPIONIC ACID COMPOSITIONS AND THEIR METHODS OF USE |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US812140A (en) * | 1901-06-14 | 1906-02-06 | Perry E Kent | Gun-barrel for pistols, rifles, and ordnance. |
| US2803654A (en) | 1955-06-24 | 1957-08-20 | Baxter Laboratories Inc | Preparation of thyroxine products |
| DE1078582B (de) * | 1958-10-29 | 1960-03-31 | Hoechst Ag | Verfahren zur Herstellung substituierter Thyropropionsaeuren |
| US3102136A (en) * | 1959-06-24 | 1963-08-27 | Warner Lambert Pharmaceutical | Process of preparing diiodinated analogs of thyronine |
| US3149153A (en) * | 1961-12-05 | 1964-09-15 | Smith Kline French Lab | 3'-substituted-3, 5-diiodothyronine and salts thereof |
| US5158978A (en) | 1990-02-05 | 1992-10-27 | British Technology Group (U.S.A.) | Thyroid hormone treatment of acute cardiovascular compromise |
| US5331000A (en) * | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
| AU3806393A (en) * | 1992-03-13 | 1993-10-05 | Sepracor, Inc. | Antipyretic and analgesic methods and compositions containing optically pure r-etodolac |
| US5284971A (en) | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
-
2001
- 2001-01-31 US US09/774,994 patent/US6534676B2/en not_active Expired - Fee Related
-
2002
- 2002-01-31 CA CA2436421A patent/CA2436421C/en not_active Expired - Fee Related
- 2002-01-31 JP JP2002560585A patent/JP2004522747A/ja active Pending
- 2002-01-31 EP EP02709310A patent/EP1432310A4/en not_active Withdrawn
- 2002-01-31 WO PCT/US2002/003162 patent/WO2002060389A2/en not_active Ceased
- 2002-01-31 AU AU2002243801A patent/AU2002243801B2/en not_active Ceased
- 2002-01-31 MX MXPA03006855A patent/MXPA03006855A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP1432310A4 (en) | 2006-06-21 |
| US20020151594A1 (en) | 2002-10-17 |
| JP2004522747A (ja) | 2004-07-29 |
| CA2436421C (en) | 2011-06-14 |
| US6534676B2 (en) | 2003-03-18 |
| EP1432310A2 (en) | 2004-06-30 |
| WO2002060389A3 (en) | 2004-04-15 |
| WO2002060389A2 (en) | 2002-08-08 |
| CA2436421A1 (en) | 2002-08-08 |
| AU2002243801B2 (en) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03006855A (es) | Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion. | |
| BR0212252A (pt) | Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero | |
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| HRP20040352B1 (en) | Use of flibanserin in the treatment of sexual disorders | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| SV1995000007A (es) | Derivados del acido micofenolico 5-substituidos. | |
| DE602004027936D1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
| WO2003092584A3 (en) | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies | |
| SE9702860D0 (sv) | New use | |
| CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
| EP1251126A3 (en) | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | |
| ATE239474T1 (de) | Verwendung von levobupivacain | |
| BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
| CY1111396T1 (el) | Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης | |
| PA8467401A1 (es) | Procedimiento para tratar la insuficiencia cardiaca | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| ES2168766T3 (es) | Preparacion farmaceutica que incluye el propeptido vwf. | |
| ATE202483T1 (de) | Immuntolerante prothrombinkomplex-präparation | |
| NO20014241D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
| DK0846173T3 (da) | Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma | |
| MX9403032A (es) | Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos. | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| ITTO20000441A0 (it) | Composizione terapeutica per la cura della psoriasi. | |
| SE0100873D0 (sv) | Method of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |